• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性呼吸困难的最小临床重要差异:每一点都有帮助。

Minimally clinically important difference in chronic breathlessness: every little helps.

机构信息

Kirkwood Hospice, Huddersfield, United Kingdom.

出版信息

Am Heart J. 2012 Aug;164(2):229-35. doi: 10.1016/j.ahj.2012.05.003.

DOI:10.1016/j.ahj.2012.05.003
PMID:22877809
Abstract

OBJECTIVES

The aim of the study was to determine the minimally clinically important difference (MCID) for breathlessness due to chronic heart failure (CHF).

BACKGROUND

The measurement of breathlessness is difficult because it is subjective and multifactorial. Statistically significant changes in assessment may not be clinically meaningful. This is the first determination of MCID in chronic breathlessness in CHF using patient-rated data.

METHODS

Measurements were made as part of a randomized, controlled, crossover trial of morphine, oxycodone, or placebo for breathlessness in CHF. Breathlessness intensity was assessed at baseline and at the end of each intervention (day 4) using 11-point numerical rating scales (NRS), modified Borg (mBorg) scales, and global impression of change (GC) in breathlessness at day 4. From these data, the change in NRS or mBorg associated with a 1-point change in GC was calculated.

RESULTS

Thirty-five patients completed all study interventions, resulting in 105 data sets. We defined MCID as a 1-point change in GC. Regression analysis found that the MCID, including 95% CIs, equaled change in average NRS breathlessness per 24 hours of 0.5 to 2.0 U (P < .001), change in worst NRS breathlessness per 24 hours of 0.4 to 2.9 (P < .001), change in average mBorg score of 0.2 to 2.0 (P < .001), and change in worst mBorg score as between 0.3 and 1.9 (P < .001). Corresponding effect size calculations lay within the 95% CIs for the regression analysis for each measure.

CONCLUSIONS

A 1-point change in NRS or mBorg score is a reasonable estimate of the MCID in average daily chronic breathlessness in CHF.

摘要

目的

本研究旨在确定慢性心力衰竭(CHF)所致呼吸困难的最小临床重要差异(MCID)。

背景

呼吸困难的测量较为困难,因为其具有主观性和多因素性。评估中出现统计学显著变化可能并不具有临床意义。这是首次使用患者自评数据确定 CHF 慢性呼吸困难的 MCID。

方法

该测量是一项关于吗啡、羟考酮或安慰剂治疗 CHF 呼吸困难的随机、对照、交叉试验的一部分。使用 11 点数字评分量表(NRS)、改良 Borg 量表(mBorg)和第 4 天呼吸困难的总体印象变化(GC)在基线和每个干预结束时(第 4 天)评估呼吸困难强度。根据这些数据,计算与 GC 变化 1 分相关的 NRS 或 mBorg 变化。

结果

35 例患者完成了所有研究干预,共产生了 105 组数据。我们将 MCID 定义为 GC 变化 1 分。回归分析发现,MCID,包括 95%CI,等于 24 小时平均 NRS 呼吸困难变化 0.5 至 2.0U(P<0.001),24 小时最差 NRS 呼吸困难变化 0.4 至 2.9(P<0.001),平均 mBorg 评分变化 0.2 至 2.0(P<0.001),最差 mBorg 评分变化 0.3 至 1.9(P<0.001)。每个测量的回归分析的效应量计算均落在 95%CI 内。

结论

NRS 或 mBorg 评分变化 1 分是 CHF 慢性日常呼吸困难 MCID 的合理估计值。

相似文献

1
Minimally clinically important difference in chronic breathlessness: every little helps.慢性呼吸困难的最小临床重要差异:每一点都有帮助。
Am Heart J. 2012 Aug;164(2):229-35. doi: 10.1016/j.ahj.2012.05.003.
2
Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial.短期阿片类药物治疗稳定型慢性心力衰竭呼吸困难:一项随机对照试验。
Eur J Heart Fail. 2011 Sep;13(9):1006-12. doi: 10.1093/eurjhf/hfr068. Epub 2011 Jun 28.
3
Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough.重复剂量的阿片类药物如果使用时间足够长,可能对慢性心力衰竭患者的呼吸困难有效。
J Palliat Med. 2013 Mar;16(3):250-5. doi: 10.1089/jpm.2012.0270. Epub 2013 Jan 31.
4
Clinically important differences in the intensity of chronic refractory breathlessness.慢性难治性呼吸困难强度的临床重要差异。
J Pain Symptom Manage. 2013 Dec;46(6):957-63. doi: 10.1016/j.jpainsymman.2013.01.011. Epub 2013 Apr 19.
5
Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study.在生命末期的诊断方面,呼吸困难的轨迹在流行率和强度方面是否存在差异?一项连续队列研究。
J Pain Symptom Manage. 2010 Apr;39(4):680-90. doi: 10.1016/j.jpainsymman.2009.09.017.
6
To What Extent Do the NRS and CRQ Capture Change in Patients' Experience of Breathlessness in Advanced Disease? Findings From a Mixed-Methods Double-Blind Randomized Feasibility Trial.在多大程度上,NRS 和 CRQ 能够捕捉晚期疾病患者呼吸困难体验的变化?一项混合方法、双盲、随机可行性试验的发现。
J Pain Symptom Manage. 2019 Sep;58(3):369-381.e7. doi: 10.1016/j.jpainsymman.2019.06.004. Epub 2019 Jun 13.
7
Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.痉挛状态0至10数字评定量表测量中变化的效度、信度及临床重要性:一项随机、双盲、安慰剂对照试验的事后分析
Clin Ther. 2008 May;30(5):974-85. doi: 10.1016/j.clinthera.2008.05.011.
8
Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea.急性心力衰竭患者报告的呼吸困难在临床上是否存在有意义的差异?来自“紧急呼吸困难”(URGENT Dyspnea)的分析。
Heart Lung. 2017 Jul-Aug;46(4):300-307. doi: 10.1016/j.hrtlng.2017.03.003. Epub 2017 Apr 19.
9
Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial.口服美沙酮控释片治疗慢性心力衰竭呼吸困难:一项随机安慰剂对照试验。
ESC Heart Fail. 2019 Dec;6(6):1149-1160. doi: 10.1002/ehf2.12498. Epub 2019 Aug 6.
10
Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness--An Exploratory Study.慢性难治性呼吸困难患者对吗啡与安慰剂的盲法偏好——一项探索性研究。
J Pain Symptom Manage. 2016 Feb;51(2):247-54. doi: 10.1016/j.jpainsymman.2015.10.005. Epub 2015 Oct 24.

引用本文的文献

1
The effect of resistance inspiratory muscle training in the management of breathlessness in patients with thoracic malignancies: a randomised controlled trial.阻力吸气肌训练对胸部恶性肿瘤患者呼吸困难管理的效果:一项随机对照试验。
Support Care Cancer. 2025 May 22;33(6):492. doi: 10.1007/s00520-025-09511-9.
2
The longitudinal impact of low-dose morphine on diurnal cortisol profiles in people with chronic breathlessness and chronic obstructive pulmonary disease (COPD): an exploratory study.低剂量吗啡对慢性呼吸急促和慢性阻塞性肺疾病(COPD)患者昼夜皮质醇水平的纵向影响:一项探索性研究。
Respir Res. 2025 Apr 23;26(1):156. doi: 10.1186/s12931-025-03230-9.
3
Ultrasound in predicting improvement in dyspnoea after therapeutic thoracentesis in patients with recurrent unilateral pleural effusion.
超声在预测复发性单侧胸腔积液患者治疗性胸腔穿刺术后呼吸困难改善情况中的应用
Eur Clin Respir J. 2024 May 5;11(1):2337446. doi: 10.1080/20018525.2024.2337446. eCollection 2024.
4
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement.急性机械通气成人患者呼吸困难:ERS/ESICM 立场声明。
Intensive Care Med. 2024 Feb;50(2):159-180. doi: 10.1007/s00134-023-07246-x. Epub 2024 Feb 22.
5
L-Menthol Olfactory Stimulation Reduced Dyspnea Sensation during the 6 min Walk Test in Patients with Chronic Breathlessness Syndrome: A Pilot Study.L-薄荷醇嗅觉刺激减轻慢性呼吸急促综合征患者6分钟步行试验期间的呼吸困难感:一项初步研究。
J Clin Med. 2023 Aug 27;12(17):5587. doi: 10.3390/jcm12175587.
6
Effects and Usefulness of Inspiratory Muscle Training Load in Patients with Advanced Lung Cancer with Dyspnea.吸气肌训练负荷对晚期肺癌伴呼吸困难患者的影响及效用
J Clin Med. 2023 May 10;12(10):3396. doi: 10.3390/jcm12103396.
7
Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis.阿片类药物治疗心力衰竭呼吸困难的效果:系统评价和荟萃分析。
Heart. 2023 Jun 26;109(14):1064-1071. doi: 10.1136/heartjnl-2022-322074.
8
Low dose of morphine to relieve dyspnea in acute respiratory failure (OpiDys): protocol for a double-blind randomized controlled study.低剂量吗啡缓解急性呼吸衰竭呼吸困难(OpiDys):一项双盲随机对照研究方案。
Trials. 2022 Sep 30;23(1):828. doi: 10.1186/s13063-022-06754-3.
9
Health-related quality of life in acute heart failure: association between patient-reported symptoms and markers of congestion.急性心力衰竭患者的健康相关生活质量:患者报告的症状与充血标志物之间的关系。
Eur J Heart Fail. 2023 Jan;25(1):54-60. doi: 10.1002/ejhf.2699. Epub 2022 Oct 14.
10
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.肥厚型心肌病的药理学治疗:从基础到临床。
Drugs. 2022 Jun;82(8):889-912. doi: 10.1007/s40265-022-01728-w. Epub 2022 Jun 13.